APA (7th ed.) Citation

HW, K., YT, L., SK, L., YH, H., YC, L., PC, L., . . . CT, Y. (2026). Correction: Real-World Outcomes of Sequential Afatinib and Osimertinib Versus Afatinib and Chemotherapy in EGFR-Mutant NSCLC: Taiwan Multicenter GIANT Study. Targeted oncology, 21(4), 609. https://doi.org/10.1007/s11523-026-01216-1

Chicago Style (17th ed.) Citation

HW, Ko, et al. "Correction: Real-World Outcomes of Sequential Afatinib and Osimertinib Versus Afatinib and Chemotherapy in EGFR-Mutant NSCLC: Taiwan Multicenter GIANT Study." Targeted Oncology 21, no. 4 (2026): 609. https://doi.org/10.1007/s11523-026-01216-1.

MLA (9th ed.) Citation

HW, Ko, et al. "Correction: Real-World Outcomes of Sequential Afatinib and Osimertinib Versus Afatinib and Chemotherapy in EGFR-Mutant NSCLC: Taiwan Multicenter GIANT Study." Targeted Oncology, vol. 21, no. 4, 2026, p. 609, https://doi.org/10.1007/s11523-026-01216-1.